| Name | Title | Contact Details |
|---|---|---|
Chris Caldwell |
Vice President, Global Sales Support | Profile |
Prashanth Urs |
Associate IT Product Director | Profile |
Charles Rapier |
Sr. Director IT, R&D Solutions | Profile |
Lincoln Bynum |
VP, Clinical R&D | Profile |
Dan Johnson |
Vice President, Executive Talent | Profile |
Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties.
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company`s non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio`s manufacturing scale to hundreds of millions of doses to support their mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
Protein Sciences Corporation is a Meriden, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LTZ Therapeutics is an immunotherapy-focused biotech company to develop novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need.
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.